Enlivex Therapeutics Ltd. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 0 | -$0.25 | -$0.25 | -$0.25 |
| Q2 2024 | 1 | -$0.22 | -$0.22 | -$0.22 |
| Q3 2024 | 0 | -$0.20 | -$0.20 | -$0.20 |
| Q4 2024 | 0 | -$0.17 | -$0.17 | -$0.17 |
| Q1 2025 | 0 | -$0.16 | -$0.16 | -$0.16 |
| Q2 2025 | 0 | -$0.16 | -$0.16 | -$0.16 |
| Q3 2025 | 0 | -$0.15 | -$0.15 | -$0.15 |
| Q4 2025 | 0 | -$0.13 | -$0.13 | -$0.13 |
Enlivex Therapeutics Ltd. Earnings Date And Information
Enlivex Therapeutics Ltd. last posted its earnings results on Friday, June 14th, 2024. The company reported $-0.22 earnings per share for the quarter, topping analysts' consensus estimates of $-0.25 by $0.03. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Enlivex Therapeutics Ltd. has generated $-2 earnings per share over the last year ($-1.56 diluted earnings per share) and currently has a price-to-earnings ratio of -1.1. Enlivex Therapeutics Ltd. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, September 9th, 2024 based on prior year's report dates.
Enlivex Therapeutics Ltd. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/30/2024 | Q2 2024 | -$0.16 | $0 | $0 | ||
| 03/29/2024 | Q1 2024 | -$0.22 | $0 | $0 | ||
| 11/09/2023 | Q4 2023 | -$0.32 | -$0.49 | -0.17 | $0 | $0 |
| 11/09/2023 | Q3 2023 | -$0.32 | -$0.32 | 0 | $0 | $0 |
| 06/16/2023 | Q2 2023 | -$0.40 | -$0.37 | 0.03 | $0 | |
| 03/31/2023 | Q1 2023 | -$0.41 | $0 | |||
| 04/10/2023 | Q4 2022 | -$0.35 | $0 | |||
| 12/02/2022 | Q3 2022 | -$0.31 | $0 | |||
| 05/27/2022 | Q2 2022 | -$0.41 | -$0.76 | -0.35 | $0 | |
| 05/27/2022 | Q1 2022 | -$0.41 | -$0.55 | -0.14 | $0 | |
| 11/19/2021 | Q4 2021 | -$0.26 | $0 | |||
| 11/19/2021 | Q3 2021 | -$0.19 | $0 | |||
| 05/28/2021 | Q2 2021 | -$0.17 | $0 | |||
| 05/28/2021 | Q1 2021 | -$0.19 | $0 | |||
| 10/30/2020 | Q4 2020 | -$0.18 | -$0.44 | -0.26 | $2.28 M | |
| 08/14/2020 | Q3 2020 | -$0.24 | -$0.16 | 0.08 | $0 | |
| 05/18/2020 | Q2 2020 | -$0.24 | -$0.23 | 0.01 | $0 | |
| 05/18/2020 | Q1 2020 | -$0.24 | -$0.07 | 0.17 | $0 | |
| 11/14/2019 | Q4 2019 | -$2.01 | $0 | |||
| 07/26/2019 | Q3 2019 | -$0.23 | $0 |
Enlivex Therapeutics Ltd. Earnings: Frequently Asked Questions
-
When is Enlivex Therapeutics Ltd.'s earnings date?
Enlivex Therapeutics Ltd. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, September 9th, 2024 based off last year's report dates.
-
Did Enlivex Therapeutics Ltd. beat their earnings estimates last quarter?
In the previous quarter, Enlivex Therapeutics Ltd. (:ENLV) reported $-0.22 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.25 by $0.03.
-
How can I listen to Enlivex Therapeutics Ltd.'s earnings conference call?
The conference call for Enlivex Therapeutics Ltd.'s latest earnings report can be listened to online.
-
How can I read Enlivex Therapeutics Ltd.'s conference call transcript?
The conference call transcript for Enlivex Therapeutics Ltd.'s latest earnings report can be read online.
-
How much profit does Enlivex Therapeutics Ltd. generate each year?
Enlivex Therapeutics Ltd. (:ENLV) has a recorded net income of $0. Enlivex Therapeutics Ltd. has generated $-1.56 earnings per share over the last four quarters.
-
What is Enlivex Therapeutics Ltd.'s price-to-earnings ratio?
Enlivex Therapeutics Ltd. (:ENLV) has a price-to-earnings ratio of -1.1 and price/earnings-to-growth ratio is -0.03.
